Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
2024年8月6日 - 5:02AM
ビジネスワイヤ(英語)
Omeros Corporation (NASDAQ: OMER), today announced that the
company will issue its financial results for the quarter ended June
30, 2024, on Wednesday, August 7, 2024, after the market closes.
Omeros management will host a conference call and webcast that same
day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss
the financial results as well as recent developments and
highlights.
Conference Call Details
For online access to the live webcast of the conference call, go
to Omeros’ website at
https://investor.omeros.com/upcoming-events.
To access the live conference call via phone, participants must
register at this link to receive a unique PIN. Once registered, you
will have two options: (1) Dial in to the conference line provided
at the registration site using the PIN provided to you, or (2)
choose the “Call Me” option, which will instantly dial the phone
number you provide. Should you lose your PIN or registration
confirmation email, simply re-register to receive a new PIN.
A replay of the call will be made accessible online at
https://investor.omeros.com/archived-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic disorders including complement-mediated
diseases, cancers, and addictive and compulsive disorders. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a biologics license application
pending before FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy. Omeros’
long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1
multi-ascending-dose clinical trial. OMS906, Omeros’ inhibitor of
MASP-3, the key activator of the alternative pathway of complement,
is advancing toward Phase 3 clinical trials for paroxysmal
nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by
the National Institute on Drug Abuse, Omeros’ lead
phosphodiesterase 7 inhibitor OMS527 is in clinical development for
the treatment of cocaine use disorder and, in addition, is being
developed as a therapeutic for other addictions as well as for a
major complication of treatment for movement disorders. Omeros also
is advancing a broad portfolio of novel immuno-oncology programs
comprised of two cellular and three molecular platforms. For more
information about Omeros and its programs, visit
www.omeros.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240805500419/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations IR@omeros.com
Omeros (NASDAQ:OMER)
過去 株価チャート
から 8 2024 まで 9 2024
Omeros (NASDAQ:OMER)
過去 株価チャート
から 9 2023 まで 9 2024